MA26568A1 - Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase et composition pharmaceutique la contenant - Google Patents

Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase et composition pharmaceutique la contenant

Info

Publication number
MA26568A1
MA26568A1 MA25356A MA25356A MA26568A1 MA 26568 A1 MA26568 A1 MA 26568A1 MA 25356 A MA25356 A MA 25356A MA 25356 A MA25356 A MA 25356A MA 26568 A1 MA26568 A1 MA 26568A1
Authority
MA
Morocco
Prior art keywords
inhibitor
glycogene
aldose
combination
pharmaceutical composition
Prior art date
Application number
MA25356A
Other languages
English (en)
Inventor
Jay Hoover Dennis
Hulin Bernard
Lakshuman Mylari Banavara
Lee Treadway Judith
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26568A1 publication Critical patent/MA26568A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Superheterodyne Receivers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Noise Elimination (AREA)
  • Enzymes And Modification Thereof (AREA)
MA25356A 1997-11-21 1998-11-19 Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase et composition pharmaceutique la contenant MA26568A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21

Publications (1)

Publication Number Publication Date
MA26568A1 true MA26568A1 (fr) 2004-12-20

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25356A MA26568A1 (fr) 1997-11-21 1998-11-19 Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase et composition pharmaceutique la contenant

Country Status (38)

Country Link
EP (1) EP1032424B9 (fr)
JP (1) JP2002504478A (fr)
KR (2) KR20010032304A (fr)
CN (1) CN1279617A (fr)
AP (1) AP911A (fr)
AR (1) AR016423A1 (fr)
AT (1) ATE205403T1 (fr)
AU (1) AU733304B2 (fr)
BG (1) BG104435A (fr)
BR (1) BR9814698A (fr)
CA (1) CA2310069A1 (fr)
DE (1) DE69801680T2 (fr)
DK (1) DK1032424T3 (fr)
DZ (1) DZ2656A1 (fr)
EA (1) EA002365B1 (fr)
ES (1) ES2161548T3 (fr)
GR (1) GR3037071T3 (fr)
GT (1) GT199800166A (fr)
HR (1) HRP20000327A2 (fr)
HU (1) HUP0100272A3 (fr)
ID (1) ID24524A (fr)
IL (1) IL135713A0 (fr)
IS (1) IS5453A (fr)
MA (1) MA26568A1 (fr)
NO (1) NO20002164L (fr)
OA (1) OA11379A (fr)
PA (1) PA8462301A1 (fr)
PE (1) PE135399A1 (fr)
PL (1) PL340643A1 (fr)
PT (1) PT1032424E (fr)
SK (1) SK7222000A3 (fr)
TN (1) TNSN98211A1 (fr)
TR (1) TR200001451T2 (fr)
UA (1) UA57811C2 (fr)
UY (1) UY25258A1 (fr)
WO (1) WO1999026659A1 (fr)
YU (1) YU30700A (fr)
ZA (1) ZA9810636B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536410A (ja) * 1999-02-12 2002-10-29 ノボ ノルディスク アクティーゼルスカブ 肥満の治療又は予防もしくは食欲の調節を目的とした薬学的組成物の製造におけるピロリジン誘導体の使用
EP1741445B1 (fr) 2000-01-21 2013-08-14 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (fr) * 2001-06-07 2002-12-12 Pfizer Products Inc. Formes salines du zopolrestat, a savoir ethanolamine, diethanolamine ou triethanolamine
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (fr) 2002-07-05 2002-12-08 Duchesnay Inc. Forme posologique pharmaceutique portant une inscription pour les femmes enceintes
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7674913B2 (en) 2003-11-12 2010-03-09 Phenomix Corporation Heterocyclic boronic acid compounds
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2006017292A1 (fr) 2004-07-12 2006-02-16 Phenomix Corporation Composes cyano contraints
WO2006055462A1 (fr) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company Derives 2-amino-4- tetraline fonctionnalisee et inhibiteurs de la glycogene phosphorylase associes
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (fr) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company Derives de 2-aminonaphtalene et inhibiteurs de la glycogene phosphorylase associes
WO2006053274A2 (fr) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company Derives de tetraline 2-amino-1-fonctionnalises et inhibiteurs correspondants de glycogene phosphorylase
EP2527337A1 (fr) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibiteurs de la 11-bêta hydroxystéroïde déshydrogénase de type I
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2622608C (fr) 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Administration d'inhibiteurs de dipeptidyl peptidase
EP2046753A2 (fr) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Inhibiteurs de type i de la 11-bêta hydroxystéroïde déshydrogénase pyridone/hydroxypyridine
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2010524953A (ja) 2007-04-17 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤
PE20090213A1 (es) 2007-05-04 2009-02-28 Bristol Myers Squibb Co Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos
WO2008137435A1 (fr) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company Agonistes [6,6] and [6,7]-bicycliques du récepteur gpr 119 couplé à la protéine g
EA018709B1 (ru) 2007-07-17 2013-10-30 Бристол-Маерс Сквибб Компани Пиридоновые агонисты сопряженного с g-белком рецептора gpr119
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
SI2531501T1 (sl) 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
MX2012011460A (es) 2010-04-08 2012-11-23 Squibb Bristol Myers Co Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
ES2559209T3 (es) 2010-04-14 2016-02-11 Bristol-Myers Squibb Company Nuevos activadores de la glucocinasa y métodos de uso de los mismos
EA201270778A1 (ru) 2010-05-06 2013-04-30 Бристол-Майерс Сквибб Компани Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
WO2011140161A1 (fr) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Analogues de benzofuranyle en tant que modulateurs de gpr119
RU2013135224A (ru) 2011-01-20 2015-03-10 Бионевиа Фармасьютикалс Инк. Композиции с модифицированным высвобождением эпалрестата или его производных и способы их использования
EP2850073B1 (fr) 2012-05-16 2017-07-19 Bristol-Myers Squibb Company Analogues de pyrimidinylpipéridinyloxypyridone en tant que modulateurs de gpr119
US9580422B2 (en) 2013-10-22 2017-02-28 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2018017910A1 (fr) 2016-07-22 2018-01-25 Bristol-Myers Squibb Company Activateurs de glucokinase et leurs procédés d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
DE3889326D1 (de) * 1988-05-27 1994-06-01 Itt Ind Gmbh Deutsche Korrekturschaltung für ein digitales Quadratur-Signalpaar.
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
EP0832066B1 (fr) * 1995-06-06 2001-09-12 Pfizer Inc. (indole-2-carbonyl-)-amides substitues en n et leurs derives, servant d'inhibiteurs de la glycogene phosphorylase
CA2342471C (fr) * 1995-06-06 2002-10-29 Judith L. Treadway Intermediaires amines de carbonyle-methyle heterocycliques

Also Published As

Publication number Publication date
OA11379A (en) 2004-01-28
UA57811C2 (uk) 2003-07-15
DE69801680D1 (de) 2001-10-18
IS5453A (is) 2000-04-14
NO20002164D0 (no) 2000-04-27
EA002365B1 (ru) 2002-04-25
KR20010032300A (ko) 2001-04-16
HRP20000327A2 (en) 2001-02-28
GR3037071T3 (en) 2002-01-31
PE135399A1 (es) 2000-01-15
UY25258A1 (es) 2000-12-29
ATE205403T1 (de) 2001-09-15
AP9801401A0 (en) 1998-12-31
EP1032424A1 (fr) 2000-09-06
KR20010032304A (ko) 2001-04-16
PA8462301A1 (es) 2000-05-24
WO1999026659A1 (fr) 1999-06-03
DE69801680T2 (de) 2002-02-07
ID24524A (id) 2000-07-20
KR100661214B1 (ko) 2006-12-26
ZA9810636B (en) 2000-05-22
GT199800166A (es) 2000-04-19
TR200001451T2 (tr) 2002-06-21
SK7222000A3 (en) 2001-09-11
PL340643A1 (en) 2001-02-12
TNSN98211A1 (fr) 2005-03-15
EP1032424B9 (fr) 2004-10-06
AR016423A1 (es) 2001-07-04
CN1279617A (zh) 2001-01-10
EA200000433A1 (ru) 2000-12-25
CA2310069A1 (fr) 1999-06-03
BG104435A (bg) 2001-01-31
HUP0100272A2 (hu) 2001-06-28
JP2002504478A (ja) 2002-02-12
HUP0100272A3 (en) 2002-11-28
EP1032424B1 (fr) 2001-09-12
IL135713A0 (en) 2001-05-20
DZ2656A1 (fr) 2003-03-22
BR9814698A (pt) 2000-10-03
DK1032424T3 (da) 2001-11-19
YU30700A (sh) 2002-12-10
AU733304B2 (en) 2001-05-10
ES2161548T3 (es) 2001-12-01
AU9555898A (en) 1999-06-15
NO20002164L (no) 2000-07-19
PT1032424E (pt) 2001-12-28
AP911A (en) 2000-12-07

Similar Documents

Publication Publication Date Title
MA26568A1 (fr) Association d'un inhibiteur d'aldose-reductase et d'un inhibiteur de glycogene-phosphorylase et composition pharmaceutique la contenant
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
MA23961A1 (fr) Benzylaminopiperidines substituees et compositions les contenant
FR2685869B1 (fr) Compositions therapeutiques a base d'inhibiteurs mixtes de la no synthase et de la cyclooxygenase.
MA26507A1 (fr) Compositions pharmaceutiques d'aerosol
MA26553A1 (fr) Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
EP0719806A3 (fr) Composition d'un copolymère d'un cyclooléfine
MA23895A1 (fr) Amides therapeutiques et compositions les contenant
ITMI951021A0 (it) Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
EP0944737A4 (fr) Representations d'interactions bimoleculaires
DZ2361A1 (fr) Dérivés de 6-phénylpyridyl-2-amine et compositionspharmaceutiques les contenant
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
DZ2461A1 (fr) Dérivés d'arylkylamines nouveaux et composition pharmaceutiques les contenant.
EP0865788A4 (fr) Inhibiteur specifique de cyclo-oxygenase 2 et agent anti-inflammatoire
FR2751540B1 (fr) Composition pharmaceutique antithrombotique
EP0826033A4 (fr) Gene de l'ataxie-telangiectasie
FR2731885B1 (fr) Installation d'etageres demontables
ID21862A (id) Komposisi-komposisi insektisida dan mitisida
ITMI950379A0 (it) Composizioni farmaceutiche contenenti un agente antiinfiammatorio e un agente antimicrobico
ID22534A (id) Komposisi-komposisi insektisida dan mitisida
FR2756735B1 (fr) Agent d'inhibition de l'expression de la proteine d'adherence icam-1 et compositions cosmetiques et pharmaceutiques le contenant
ID22068A (id) Komposisi-komposisi insektisida dan mitisida
FR2739382B1 (fr) Fraction ribosomale et composition la contenant
FI963263L (fi) Bromelaiinin lääkinnällinen käyttö
IL111467A0 (en) Pharmaceutical compositions comprising 7 beta -substituted -4-aza 5 alpha -cholestan-3-ones and 5 alpha reductase 1 inhibitors